No IPO? No Problem
Helix Takes Road Less Traveled to Reach U.S. Capital Markets
By Jennifer Boggs
Monday, March 21, 2011
Last week, HIV drug developer Koronis Pharmaceuticals Inc. said it was exploring a range of financing options, including a possible listing on London's AIM exchange, to access adequate funding for mid- and late-stage activities. But one alternative the Seattle-based firm won't be considering is a traditional initial public offering (IPO) on Nasdaq.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.